Phylogica has a strong intellectual property portfolio around its proprietary Phylomer® peptide technology with over sixteen patent families comprising multiple granted/ allowed patents covering international markets, including the  US, and  Australia. Phylomer® peptides, being fragments of naturally occurring proteins sourced from ancient bacteria, have a different origin than antibodies and hence are not bound by traditional antibody patents.

Phylogica’s patent families cover methods of making the Phylomer® peptide libraries, methods of screening them and composition-of-matter claims for Phylomer®  libraries and individual Phylomer® peptides discovered for therapeutic and diagnostic applications.